Sun Pharma response to import ban inadequate - FDA

Tue May 20, 2014 10:22pm IST

A logo of Sun Pharmaceutical Industries Ltd at its research and development center in Mumbai April 7, 2014.  REUTERS/Danish Siddiqui/Files

A logo of Sun Pharmaceutical Industries Ltd at its research and development center in Mumbai April 7, 2014.

Credit: Reuters/Danish Siddiqui/Files

Related Topics

Stocks

   

REUTERS - Generic drugmaker Sun Pharmaceutical Industries Ltd's (SUN.NS) response to an import ban on one of its plants lacked "sufficient corrective actions," the U.S. Food and Drug Administration said in a warning letter published on Tuesday.

The FDA banned imports from Sun Pharma's Karkhadi plant in Gujarat in March, but the reason for the ban was not clear at that time.

In the warning letter dated May 7 and posted on the FDA website on Tuesday, the regulator said Sun Pharma failed to ensure laboratory records had complete data and that manufacturing staff had inadequate training and experience.

"Your firm frequently performs 'unofficial testing' of samples, disregards the results, and reports results from additional tests," the FDA said in the letter addressed to Sun Pharma CEO Subramanian Kalyanasundaram. (link.reuters.com/pyx49v)

A Sun Pharma spokesman told Reuters on Tuesday that the warning letter shows that the U.S. FDA does not agree with the company's response.

The Karkhadi plant, which makes the antibiotic cephalosporin, is one of Sun Pharma's 25 manufacturing plants.

Sun Pharma, which is planning to buy its struggling rival Ranbaxy Laboratories Ltd (RANB.NS) for $3.2 billion, had said in March that the import ban would have negligible financial impact.

The FDA has unleashed a wave of restrictions, warnings and bans on Indian generic drug firms over the past one year, citing serious manufacturing and quality control problems.

(Reporting by Esha Dey in Bangalore and Zeba Siddiqui in Mumbai; Editing by Sriraj Kalluvila)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Market Eye

Sensex, Nifty rise to second consecutive record high

Sensex, Nifty rise to second consecutive record high

The BSE Sensex and Nifty on Friday rose to their second consecutive record highs. The 30-share Sensex surged as much as 1.3 percent to an all-time high of 27,706.80. The broader Nifty gained as much as 1.28 percent to a record of 8,275.15.  Full Article 

REUTERS SHOWCASE

Cost Cutting

Cost Cutting

PM Narendra Modi boots officials out of the first class cabin  Full Article 

Airtel Profit Jumps

Airtel Profit Jumps

Bharti Q2 net profit more than doubles   Full Article 

Leisure Riding

Leisure Riding

Harley-Davidson woos affluent young Indians with bike culture  Full Article 

Maruti Earnings

Maruti Earnings

Maruti Suzuki net profit up 29 percent, beats estimates.  Full Article 

ICICI Results

ICICI Results

ICICI Bank Q2 profit up 15 percent, beats estimates.  Full Article 

Moody's on India

Moody's on India

Moody's welcomes India's policy steps, but wants to see more.  Full Article 

End Of QE

End Of QE

U.S. Fed ends bond buying, exhibits confidence in U.S. recovery.  Full Article 

Cook Comes Out

Cook Comes Out

Apple's Cook: "I'm proud to be gay"  Full Article 

Refining Margins

Refining Margins

BPCL aims to double refining margins with refinery expansion.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage